Larimar Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $285.7M
- Price
- $2.75
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.08%
- Volume
- 717.4K
About
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.
Quick stats
Shares outstanding103.9M
Computed float61.7M
Float / shares59.4%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001374690
Websitehttps://www.larimartx.com
AI Summary
AI-generated1/20
minorbullishexecutive change
Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer
Larimar Therapeutics appointed John Harlow as President and Chief Operating Officer, effective September 29, 2026, reporting to CEO Carole Ben-Maimon.
Harlow brings more than 25 years of biopharma commercial and operational experience, most recently as Chief Commercial Officer of Esperion, with prior roles at Melinta, Baudax Bio, Recro Pharma, Endo, Novartis and Janssen.
The hire signals launch-readiness for nomlabofusp, Larimar's lead candidate for Friedreich's ataxia, as the company nears potential accelerated approval and prepares to scale commercially.
In connection with the appointment, Harlow received Nasdaq Rule 5635(c)(4) inducement awards: options on 800,000 shares vesting over four years and RSUs on 50,000 shares vesting annually over four years.